Jim Simons Cogent Biosciences, Inc. Transaction History

Renaissance Technologies LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$4.38 - $9.02 $1.2 Million - $2.47 Million	273,400 Added 1040.81%	299,668 $2.01 Million
Q4 2023 Feb 13, 2024	BUY	$4.06 - $10.08 $106,648 - $264,781	26,268 New	26,268 $154,000
Q1 2023 May 12, 2023	BUY	$10.04 - $15.5 $617,138 - $952,754	61,468 New	61,468 $663,000
Q3 2022 Nov 14, 2022	SELL	$9.39 - $16.99 $250,074 - $452,477	-26,632 Reduced 63.71%	15,168 $226,000
Q2 2022 Aug 12, 2022	BUY	$3.92 - $9.73 $118,776 - $294,819	30,300 Added 263.48%	41,800 $377,000
Q1 2022 May 13, 2022	BUY	$5.31 - $8.7 $61,064 - $100,049	11,500 New	11,500 $86,000
Q1 2021 May 13, 2021	SELL	$7.47 - $12.34 $242,364 - $400,371	-32,445 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$9.04 - $13.01 $293,302 - $422,109	32,445 New	32,445 $364,000

172

114M

56.7K

40.4K

Ticker COGT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,758,300
Market Cap $612M
Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.